… Aliskiren is the first of a new class of antihypertensive agents. Aliskiren is a new renin inhibitor
… be efficacious in hypertensive patients after once-daily oral dosing. In short-term studies, it …

… levels by direct inhibition of renin. So far, specific renin inhibitors lacked potency and/or
oral … We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an …

… orally active renin inhibitor aliskiren was at least as effective at suppressing the RAAS as the
ACE inhibitor … one week of treatment with 75 mg of aliskiren reduced plasma angiotensin II …

… Renin inhibitors block the RAAS at the highest … Aliskiren is the first in a new class of orally
active, non-peptide, low molecular weight renin inhibitors, and so far the only renin inhibitor …

… renin inhibitor aliskiren strongly reduces PRA even in the absence of this artefact, which
appears common to all conventional PRA assays and leads to overestimation of renin inhibition. …

… years before the first inhibitors of renin were available for clinical research. Here, we describe
the discovery and development of aliskiren, an orally active renin inhibitor, which became …

… Aliskiren is the first member of the new class of orally active direct renin inhibitors recently …
Aliskiren directly inhibiting the renin and reducing the formation of angiotensin II, which is the …

… The first generation of orally active renin inhibitors … aliskiren is the first non-peptide orally
active renin inhibitor to progress to phase-III clinical trials. It might become the first renin inhibitor …

… The results of this study show that aliskiren is a safe, orally active renin inhibitor that
lowers BP. Despite the wealth of evidence that reduction of BP provides important protection, …

… In conclusion, once-daily oral treatment with the direct renin inhibitor aliskiren provided
antihypertensive efficacy comparable to an ARB with placebo-like tolerability in patients with …